Microdialysis in Drug Development (Record no. 95229)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03381nam a22004575i 4500 |
| 001 - CONTROL NUMBER | |
| control field | 978-1-4614-4815-0 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20140220082816.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 120913s2013 xxu| s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781461448150 |
| -- | 978-1-4614-4815-0 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/978-1-4614-4815-0 |
| Source of number or code | doi |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RS380 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RS190-210 |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | TDCW |
| Source | bicssc |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED072000 |
| Source | bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.19 |
| Edition number | 23 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Müller, Markus. |
| Relator term | editor. |
| 245 10 - TITLE STATEMENT | |
| Title | Microdialysis in Drug Development |
| Medium | [electronic resource] / |
| Statement of responsibility, etc | edited by Markus Müller. |
| 264 #1 - | |
| -- | New York, NY : |
| -- | Springer New York : |
| -- | Imprint: Springer, |
| -- | 2013. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | XI, 338 p. 55 illus., 29 illus. in color. |
| Other physical details | online resource. |
| 336 ## - | |
| -- | text |
| -- | txt |
| -- | rdacontent |
| 337 ## - | |
| -- | computer |
| -- | c |
| -- | rdamedia |
| 338 ## - | |
| -- | online resource |
| -- | cr |
| -- | rdacarrier |
| 347 ## - | |
| -- | text file |
| -- | |
| -- | rda |
| 490 1# - SERIES STATEMENT | |
| Series statement | AAPS Advances in the Pharmaceutical Sciences Series, |
| International Standard Serial Number | 2210-7371 ; |
| Volume number/sequential designation | 4 |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Introduction to the Microdialysis Technology -- Recovery and Calibration Techniques: Toward Quantitative Microdialysis -- Analytical Considerations for Microdialysis Sampling -- Regulatory Aspects of Microdialysis: A United States Food & Drug Administration Perspective -- Microdialysis in CNS PKPD Research: Unraveling Unbound Concentrations -- Microdialysis in Antibiotic Research -- Skin and Transdermal Drug Delivery: Advantages and Challenges -- Translational Approaches For Predicting CNS Drug Effects Using Microdialysis -- Extracellular Amyloid-β Protein Dynamics in Alzheimer's Disease -- Microdialysis in Pain Research -- Microdialysis in Ocular Drug Development -- Microdialysis in Metabolic Research -- High Molecular Weight Targets and Treatments Using Microdialysis -- Complementary Techniques – Positron Emission Tomography -- Open Flow Microperfusion: An Alternative Method to Microdialysis? -- Microdialysis in Internal Organs and Tumors. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | In vivo target site concentrations are probably the most important determinant of drug effects. Traditionally, linking drug concentrations to drug effects has been accomplished by modelling blood-derived data, mostly because a direct quantification of tissue concentrations has been beyond technical reach. Today, a direct measurement of target site concentrations is possible by employing microdialysis or complementary approaches such as imaging technologies. Microdialysis, initially conceived in the 1970ies, has become a standard tool in drug development. This comprehensive overview of current microdialysis technology covers general and disease-specific aspects of microdialysis by international experts in the field. It provides useful information for colleagues in academia and industry who are interested PK-PD aspects of drug development. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Medicine. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmaceutical technology. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Biomedicine. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmaceutical Sciences/Technology. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Biomedicine general. |
| 710 2# - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY | |
| Title | Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Display text | Printed edition: |
| International Standard Book Number | 9781461448143 |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | AAPS Advances in the Pharmaceutical Sciences Series, |
| -- | 2210-7371 ; |
| Volume number/sequential designation | 4 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | http://dx.doi.org/10.1007/978-1-4614-4815-0 |
| 912 ## - | |
| -- | ZDB-2-SBL |
No items available.